German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella.
Menichella joined the company in 2017 to run its US operations, which are in Boston. He took over the CEO role from Hoerr in 2018.
In its statement announcing the transition, CureVac credited Menichella with advancing the company’s clinical-stage programs, the start of its vaccine program targeting the newly emerged coronavirus, and collaboration deals with Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Genmab (NASDAQ: GMAB). But it provided no explanation as why he is leaving and included no comment from Menichella.